Yahoo54m
An experimental drug drove people to lose 23% of their body weight. It’s still seen as a disappointment
Lilly answered with Mounjaro and Zepbound, approved in 2022 and 2023 for diabetes and weight loss, respectively. They use the ...
Novo Nordisk's dosing in CagriSema obesity drug trial puzzles investors
Pedersen and Mariam Sunny LONDON/COPENHAGEN (Reuters) -Novo Nordisk shareholders were seeking on Friday to find out why such ...
Novo Nordisk’s next-generation weight-loss drug matches Lilly’s Zepbound in major trial, but doesn’t surpass it
Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...